GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biocon Ltd (NSE:BIOCON) » Definitions » Notes Receivable

Biocon (NSE:BIOCON) Notes Receivable : ₹0 Mil (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is Biocon Notes Receivable?

Biocon's Notes Receivable for the quarter that ended in Mar. 2024 was ₹0 Mil.


Biocon Notes Receivable Historical Data

The historical data trend for Biocon's Notes Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biocon Notes Receivable Chart

Biocon Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Notes Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Biocon Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Notes Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Biocon Notes Receivable Calculation

Notes Receivable is an unconditional promise to receive a definite sum of money at a future date(s) within one year of the balance sheet date or the normal operating cycle, whichever is longer.


Biocon Notes Receivable Related Terms

Thank you for viewing the detailed overview of Biocon's Notes Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Biocon (NSE:BIOCON) Business Description

Traded in Other Exchanges
Address
20th KM, Hosur Road, Electronics City, Bengaluru, KA, IND, 560 100
Biocon Ltd is a biopharmaceutical company that develops biotechnology therapies for diseases. The company is focused on developing, manufacturing, and supplying novel and biosimilar pharmaceuticals for diabetes, cancer, and autoimmune conditions. Biocon has four reportable segments: Generics, Biosimilars, Novel Biologics (Novels), and Research services (Research). The company provides integrated contract research and manufacturing services to pharmaceutical and biotechnology companies through its subsidiary Syngene.

Biocon (NSE:BIOCON) Headlines

No Headlines